Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities researchers at Zacks Research boosted their Q2 2024 EPS estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, April 2nd. Zacks Research analyst R. Department now expects that the company will post earnings of $1.27 per share for the quarter, up from their previous forecast of $1.26. The consensus estimate for Bausch Health Companies' current full-year earnings is $4.97 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2024 earnings at $1.43 EPS, Q4 2024 earnings at $1.49 EPS, FY2024 earnings at $5.24 EPS, Q2 2025 earnings at $1.25 EPS, Q3 2025 earnings at $1.47 EPS, Q1 2026 earnings at $1.32 EPS and FY2026 earnings at $6.67 EPS.
Bausch Health Companies (TSE:BHC - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported C$1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of C$1.36 by C$0.19. Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 6.76%. The business had revenue of C$3.28 billion for the quarter, compared to analyst estimates of C$3.05 billion.
Separately, Royal Bank of Canada increased their price target on shares of Bausch Health Companies from C$8.00 to C$9.00 and gave the stock a "sector perform" rating in a research report on Friday, February 23rd.
View Our Latest Stock Report on BHC
Bausch Health Companies Stock Down 1.7 %
Shares of TSE:BHC traded down C$0.23 during midday trading on Wednesday, reaching C$13.60. The company had a trading volume of 664,587 shares, compared to its average volume of 338,872. Bausch Health Companies has a one year low of C$7.56 and a one year high of C$15.43. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.30 and a quick ratio of 0.58. The stock has a market capitalization of C$4.97 billion, a P/E ratio of -6.18, a PEG ratio of 0.21 and a beta of 0.83. The stock's fifty day moving average price is C$12.22 and its 200-day moving average price is C$10.94.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
